hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06378021 id: Calcium chloride in CABG briefTitle: Role of Calcium Chloride Injection in Alleviating Atrial Fibrillation Post CABG overallStatus: RECRUITING date: 2024-03-14 date: 2025-03 date: 2025-04 date: 2024-04-22 date: 2024-04-22 name: Helwan University class: OTHER briefSummary: This study hypothesize that injecting calcium chloride (CaCl2) into the major atrial ganglionated plexus (GPs) during on pump Coronary artery bypass graft (CABG) can reduce the incidence of Post operative Atrial fibrillation in the first 7 days after surgery.The study is designed to be prospective interventional study two armed RCT for on pump CABG patient.
The intervention arm will be injected with Calcium chloride in the four major atrial ganglionic plexus The control arm will be injected with sodium chloride to determine the effect of Calcium chloride on Post CABG Atrial fibrillation conditions: Atrial Fibrillation studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 100 type: ESTIMATED name: Calcium Chloride name: Sodium Chloride 0.9% Inj measure: Change in number of patients who developed Atrial fibrillation measure: Change in length of hospital stay sex: ALL minimumAge: 18 Years maximumAge: 74 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ain shams university status: RECRUITING city: Cairo state: Abassia Cairo zip: 02 country: Egypt name: Mohamed A Gamal, Ass prof role: CONTACT phone: 010080827060 phoneExt: 02 name: Abdelhameed I Ebid, Prof role: PRINCIPAL_INVESTIGATOR lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06378008 id: 300100 briefTitle: A Clinical Study to Evaluate the Anti-Sensitivity Effect of a Calcium Sodium Phosphosilicate Toothpaste in a Population of Dentin Hypersensitivity Sufferers overallStatus: RECRUITING date: 2024-04-16 date: 2024-09-13 date: 2024-09-13 date: 2024-04-22 date: 2024-04-22 name: HALEON class: INDUSTRY briefSummary: The aim of this study is to confirm the clinical dentin hypersensitivity (DH) efficacy of a 5 percent (%) calcium sodium phosphosilicate (CSPS) toothpaste. conditions: Dentin Sensitivity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: INVESTIGATOR count: 234 type: ESTIMATED name: CSPS toothpaste name: Regular fluoride toothpaste (Crest Cavity Protection) measure: Change from Baseline in Schiff Sensitivity Score at Day 56 measure: Change from Baseline in Tactile Threshold at Day 56 measure: Change from Baseline in Schiff Sensitivity Score at Days 3, 7, 14 and 28 measure: Change from Baseline in Tactile Threshold at Days 3, 7, 14 and 28 measure: Change from Baseline in Impact on Everyday Life (Section 1 of Dentin Hypersensitivity Experience Questionnaire [DHEQ-48], Question [Q]7-9) at Days 28 and 56 measure: Change from Baseline in DHEQ Total Score (Section 2, Question Q1-34) at Days 28 and 56 measure: Change from Baseline in DHEQ Restrictions Domain (Section 2, Q1-4) Score at Days 28 and 56 measure: Change from Baseline in DHEQ Adaptation Domain Score (Section 2, Q5-16) at Days 28 and 56 measure: Change from Baseline in DHEQ Social Impact Domain (Section 2, Q17-21) Score at Days 28 and 56 measure: Change from Baseline in DHEQ Emotional Impact Domain (Section 2, Q22-29) Score at Days 28 and 56 measure: Change from Baseline in DHEQ Identity Domain (Section 2, Q30-34) Score at Days 28 and 56 measure: Change from Baseline in Global Oral Health (Section 2, Q35) Score at Days 28 and 56 measure: Change from Baseline in Effect on Life Overall (Section 2, Q36-39) Score at Days 28 and 56 sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: All Sum Research status: RECRUITING city: Mississauga state: Ontario zip: L5N 6J2 country: Canada name: C R Goyal, Dr role: CONTACT lat: 43.5789 lon: -79.6583 hasResults: False
nctId: NCT06377995 id: OST1_013 briefTitle: Effectiveness of an Intervention Plan Aimed at the Diaphragm in Chronic Non-specific Neck Pain overallStatus: NOT_YET_RECRUITING date: 2024-09 date: 2024-12-31 date: 2024-12-31 date: 2024-04-22 date: 2024-04-22 name: Escola Superior de Tecnologia da Saúde do Porto class: OTHER briefSummary: The aim of this study is to analyse the effectiveness of an intervention plan targeting the diaphragm, namely stretching technique, neuromuscular diaphragm and phrenic centre inhibition, in the treatment of chronic non-specific neck pain. conditions: Chronic Neck Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: Double whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 45 type: ESTIMATED name: Placebo technique name: Diaphragm protocol measure: Change in the intensity of pain in the cervical spine after applying the diaphragm intervention plan measure: Changes in range of motion after applying the diaphragm targeted protocol measure: Changes in pain level one week after the intervention measure: Changes in range of motion one week later sex: ALL minimumAge: 18 Years maximumAge: 35 Years stdAges: ADULT facility: Escola Superior de Saúde do Porto city: Porto zip: 4200-072 country: Portugal name: Natália MO Campelo, PhD role: CONTACT phone: +35122 206 1000 email: nmc.ess.ipp@gmail.com name: Natália MO Campelo, PhD role: PRINCIPAL_INVESTIGATOR lat: 41.14961 lon: -8.61099 hasResults: False
nctId: NCT06377982 id: SCCP001 briefTitle: Human Umbilical Cord Blood Infusion in Patients With Cerebral Palsy overallStatus: NOT_YET_RECRUITING date: 2024-09 date: 2026-09 date: 2026-12 date: 2024-04-22 date: 2024-04-22 name: StemCyte Taiwan Co., Ltd. class: INDUSTRY briefSummary: A phase I, randomized, double-blind, placebo-controlled clinical study to assess the safety and efficacy of allogeneic human umbilical cord blood infusion in children with cerebral palsy conditions: Cerebral Palsy studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 12 type: ESTIMATED name: hUCB measure: safety-TEAE sex: ALL minimumAge: 1 Year maximumAge: 18 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06377969 id: 75269 briefTitle: Prospective Evaluation of Effectiveness and Safety of Closed-Loop Spinal Cord Stimulation in Treating Patients With Chronic Pelvic Pain overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2026-12-31 date: 2027-06-30 date: 2024-04-22 date: 2024-04-26 name: Stanford University class: OTHER briefSummary: Spinal cord stimulation (SCS) is an effective treatment for patients with chronic pelvic pain. The investigators will evaluate how safe and effective closed-loop spinal cord stimulation is in treating these patients; closed-loop spinal cord stimulation is a more novel method in delivering spinal cord stimulation that controls energy output of the device based on real-time feedback on how the device is stimulating the spinal cord. conditions: Chronic Pelvic Pain Syndrome studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Pilot prospective single arm interventional study primaryPurpose: TREATMENT masking: NONE count: 10 type: ESTIMATED name: ECAP (Evoked Compound Action Potential)-controlled Closed-Loop Spinal Cord Stimulation measure: Change in Pain Intensity measure: Change in Disability measure: Patient Global Impression Change measure: Change in Quality of Life measure: Change in Pain Catastrophizing Scale measure: Change in sleep quality measure: Change in Social Functioning sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06377956 id: XRGao briefTitle: The Associations Between Gut Length, Gut Microbiota and Food Assimilation overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-06-01 date: 2025-06-01 date: 2024-04-22 date: 2024-04-22 name: Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences class: OTHER briefSummary: The purpose of this observational study is to explore the correlation between human gut length and food absorption rates. This will include characterization of gut length, total food intake energy, fecal calories, urinary calories, body composition, food intake behavior, genetics and gut microbiota in the small intestine. Researchers expect to recruit up to 100 healthy volunteers. conditions: Gut Length conditions: Food Assimilation Efficiency studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 100 type: ESTIMATED name: Observation without intervention measure: Gut length measure: Energy intake measure: Fecal calorie measure: Urine calorie measure: Weight measure: Height measure: Waist circumferences measure: Hip circumferences measure: Bone mass measure: Fat mass measure: Fat free mass measure: Blood pressure measure: Heart rate measure: Resting energy expenditure measure: Thermic effect of food measure: Body shape measure: Microbiome measure: Metabolites measure: Gut transit time measure: Food macronutrient content measure: Feces macronutrient content measure: Total daily water volume measure: Total daily urine volume measure: Physical activity measure: Bristol Stool Scale sex: ALL minimumAge: 18 Years maximumAge: 40 Years stdAges: ADULT facility: Shenzhen Institute of Advanced Technology city: Shenzhen state: Guangdong zip: 518055 country: China name: John R Speakman, PhD role: CONTACT phone: 13466654659 email: j.speakman@abdn.ac.uk lat: 22.54554 lon: 114.0683 hasResults: False
nctId: NCT06377943 id: SIAT-IRB-240415-H0718 briefTitle: The Interaction Between Resting Metabolic Rate, Physical Activity and Thyroid Hormone in Females overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-07-31 date: 2024-10-31 date: 2024-04-22 date: 2024-04-22 name: Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences class: OTHER briefSummary: This Study is focused on the interaction between resting metabolic rate (RMR), physical activity (PA), and thyroid hormones (TH). TH controls almost all the cell activities of the body so, it is known as one of the major regulatory hormones. This is the reason for individuals who suffer from thyroid disorders show abnormal metabolism. Recently it was suggested that interindividual variations in thyroid hormone levels also influence daily physical activity. conditions: Thyroid conditions: Physical Activities conditions: Resting Energy Expenditure studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 50 type: ESTIMATED measure: Body weight measure: Height measure: Waist and Hip circumferences measure: Fat mass measure: Far free mass measure: Bone mass measure: Resting Metabolism measure: Physical activity measure: Thyroid hormone measure: Total energy expenditure sex: FEMALE minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT hasResults: False
nctId: NCT06377930 id: RAP-219-FOS-201 briefTitle: Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2025-03-01 date: 2025-06-01 date: 2024-04-22 date: 2024-04-26 name: Rapport Therapeutics Inc. class: INDUSTRY briefSummary: This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine if RAP-219 works and is safe in patients with Refractory Focal Epilepsy. conditions: Focal Onset Seizures studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: RAP-219 measure: Efficacy in reducing frequency of RNS-recorded long episodes in participants with FOS measure: Measurement of estimated electrographic seizure frequency from available RNS-recorded episodes measure: Measurement of Clinical Seizure Frequency measure: Change in seizure severity measure: Global Impression of Change measure: Pharmacokinetic parameters sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06377917 id: 2304-BRG-057-JF briefTitle: Investigating Micro-Manipulation Procedures for Assisted Hatching Timing acronym: IMPACT overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-05 date: 2026-05 date: 2024-04-22 date: 2024-04-22 name: Reproductive Medicine Associates of New Jersey class: OTHER briefSummary: This study aims to assess the clinical significance of cleavage stage (Day 3) assisted hatching compared to assisted hatching at the blastocyst stage (Day 5,6,7) of embryo development at the time of trophectoderm (TE) biopsy for patients undergoing in vitro fertilization (IVF) and preimplantation genetic testing for aneuploidy (PGT-A) for treatment of their infertility. conditions: Infertility studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 75 type: ESTIMATED name: Laser Assisted Hatching measure: Blastulation Rate measure: Embryo morphologic grade measure: Timing of blastulation measure: Aneuploidy rate measure: Positive pregnancy rate measure: Sustained implantation rate measure: Pregnancy loss rate measure: Live birth rate sex: FEMALE minimumAge: 18 Years maximumAge: 42 Years stdAges: ADULT facility: Reproductive Medicine Associates of New Jersey city: Marlton state: New Jersey zip: 08053 country: United States name: Christine V Whitehead, MS, BSN, RN role: CONTACT phone: 973-656-2841 email: clinicalresearchteam@ivirma.com name: Caroline Zuckerman, BS, RN role: CONTACT phone: 19736562841 email: clinicalresearchteam@ivirma.com name: Jason Fransiak, MD role: PRINCIPAL_INVESTIGATOR name: Kevin Lambrese, PhD role: PRINCIPAL_INVESTIGATOR lat: 39.89122 lon: -74.92183 hasResults: False
nctId: NCT06377904 id: 2023-A02125-40 briefTitle: Clinical and Therapeutic Characteristics of Geriatric Patients Hospitalized for Heart Failure (AGING HF Study (AGe and Heart Failure IN Geriatrics)) acronym: AGING HF overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2027-04 date: 2028-04 date: 2024-04-22 date: 2024-04-22 name: Gérond'if class: OTHER briefSummary: This retrospective (between April 2020 and December 2023) then prospective (between January 2024 and August 2026), non-interventional cohort study has as its main objective to evaluate the clinical and therapeutic characteristics of patients aged 75 and over hospitalized in geriatrics for heart failure and also to evaluate the clinical characteristics and triggering factor(s) of acute heart failure. conditions: Patients Hospitalized in Geriatrics for Heart Failure conditions: Patients Aged 75 and Over studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: OTHER count: 810 type: ESTIMATED measure: Evaluate the clinical and therapeutic characteristics of elderly patients hospitalized in geriatrics for heart failure measure: Factors associated with patients hospitalization or rehospitalization sex: ALL minimumAge: 75 Years stdAges: OLDER_ADULT hasResults: False
nctId: NCT06377878 id: Pro00008369 briefTitle: The Preeclampsia Registry acronym: TPR overallStatus: RECRUITING date: 2013-09-01 date: 2040-05 date: 2040-05 date: 2024-04-22 date: 2024-04-22 name: Preeclampsia Foundation class: OTHER briefSummary: The purpose of The Preeclampsia Registry is to collect and store medical and other information from women who have been medically diagnosed with preeclampsia or a related hypertensive (high blood pressure) disorder of pregnancy such as eclampsia or HELLP syndrome, their family members, and women who have not had preeclampsia to serve as controls. Information from participants will be used for medical research to try to understand why preeclampsia occurs, how to predict it better, and to develop experimental clinical trials of new treatments. The Registry will consist of a web-based survey and mechanism for collecting and reviewing medical records. This data will be utilized for immediate investigator-driven cross-sectional research projects (after proposal review by the Registry's scientific advisory board and as directed by the PI). Participants may also choose to be contacted regarding possible participation in future studies, about providing a biospecimen, as well as investigator-driven clinical trials. The Registry is anticipated to exist long-term and to serve as a foundation of participants from which to draw for studies of preeclampsia, anticipated to evolve as our scientific understanding of preeclampsia evolves. conditions: Preeclampsia conditions: Eclampsia conditions: HELLP Syndrome conditions: Toxemia conditions: Hypertensive Disorder of Pregnancy studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: OTHER count: 20000 type: ESTIMATED measure: Self Reported Diagnosis of Preeclampsia and Hypertensive Disorders of Pregnancy Confirmed by Medical Records sex: ALL minimumAge: 13 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Preeclampsia Foundation status: RECRUITING city: Melbourne state: Florida zip: 32940 country: United States name: VeeAnn Argyle role: CONTACT phone: 321-421-6957 email: Registry@preeclampsia.org name: Eleni Z Tsigas, BA role: PRINCIPAL_INVESTIGATOR name: Hilary Gammill, MD role: SUB_INVESTIGATOR name: James Roberts, MD role: SUB_INVESTIGATOR lat: 28.08363 lon: -80.60811 hasResults: False
nctId: NCT06377865 id: endocrine dis & B thalassemia briefTitle: Thyroid Function , HbA1c in Relation to Ferritin Level in Adullt Patient e B Thalassemia overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-11-01 date: 2026-05-01 date: 2024-04-22 date: 2024-04-22 name: Assiut University class: OTHER briefSummary: to evaluate thyroid function ,HbA1C,\&lipid profile in thalassemic patient to correlate thyroid function , Hba1c , lipid profile e ferritin level in thalassemic patient conditions: B Thalassemia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 72 type: ESTIMATED measure: Thyroid function ,Hba1c in relation to ferritin level in adult patients with beta thalassemia sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06377852 id: Pro00075309 briefTitle: The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study overallStatus: NOT_YET_RECRUITING date: 2024-10-28 date: 2028-08-31 date: 2028-09-01 date: 2024-04-22 date: 2024-04-22 name: American Society of Clinical Oncology class: OTHER name: Patient-Centered Outcomes Research Institute briefSummary: The purpose of this study is to generate evidence on an alternative dosing strategy for CDK4/6 inhibitors to help more patients with MBC (age ≥ 65 years) tolerate side effects and stay on treatment longer, to derive the most clinical benefit from these drugs.
The primary objective of the CDK Study is to compare TTD on the approved dosing for palbociclib (125 mg orally daily on days 1-21 of 28-day cycle) or ribociclib (600 mg orally daily on days 1-21 of 28-day cycle) vs. TTD using titrated dosing approach with the same schedule but starting at a lower dose of palbociclib (100 mg or 75 mg) or ribociclib (400 mg or 200 mg) and escalating the dose if well-tolerated in combination with provider/patient choice endocrine therapy (AI or fulvestrant) in patients age 65 or older with HR+/HER2- MBC. The secondary and exploratory objectives will generate evidence needed to personalize treatment decisions by comparing patient-centric secondary outcomes and evaluating baseline factors.
Together with their treating physician, participants will choose the CDK4/6 inhibitor (palbociclib or ribociclib) and which endocrine therapy (aromatase inhibitor or fulvestrant) of their choice but will be randomized to either Arm 1 (indicated dosing) or Arm 2 (titrated dosing). conditions: Metastatic Breast Cancer studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: 500 patients will be enrolled, 250 per arm (Arm 1 being indicated dose, Arm 2 being titrated dose). primaryPurpose: TREATMENT masking: NONE count: 500 type: ESTIMATED name: Palbociclib name: Ribociclib measure: Time to Treatment Discontinuation (TTD) measure: Toxicity (grade 3-4 AEs) measure: Event-Free survival (EFS) measure: Quality of life assessed by patient reported outcomes measure: Time to dose reduction and escalation measure: Reason for not escalating measure: Treatment received (missed doses, cumulative dose, etc.) measure: Healthcare utilization (ED visits, hospital admissions, etc.) measure: Body Mass Index sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT hasResults: False
nctId: NCT06377839 id: N-20230048 briefTitle: Pain After Removal of Mandibular Third Molars With or Without Advanced Platelet-rich Fibrin overallStatus: RECRUITING date: 2024-01-10 date: 2024-04-17 date: 2025-12-01 date: 2024-04-22 date: 2024-04-22 name: Aalborg University Hospital class: OTHER name: Aalborg University briefSummary: Pain is the most common complication following surgical removal of an impacted mandibular third molar. Several risk factors may increase the intensity and duration of pain following removal of mandibular third molars. Acute postoperative pain can transcript into postoperative chronic pain without an explainable reason or a specific risk factor. The use of advanced platelet-rich fibrin in the extraction socket following surgical removal of mandibular third molar have diminished the intensity and duration of acute postoperative pain and facilitated improved wound healing. The objective of the present study is therefore to identified specific risk factors and predictors for developing postoperative chronic pain following surgical removal of mandibular third molars with or without advanced platelet-rich fibrin applied in the extraction socket using epigenetic modulation. conditions: Pain Syndrome studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized controlled trial primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 80 type: ESTIMATED name: Advanced platelet-rich fibrin in the ekstraction socket measure: Assessment of postoperative pain by using Visual Analoque scale measure: Assessment of quality of life sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Oral and Maxillofacial surgery, Aalborg University Hospital status: RECRUITING city: Aalborg state: Nordjylland zip: 9000 country: Denmark name: Thomas Starch-Jensen, Professor role: CONTACT phone: +45 23266370 email: thomas.jensen@rn.dk lat: 57.048 lon: 9.9187 hasResults: False
nctId: NCT06377826 id: RCRAHS-ISB/REC/MS-PT/01813 briefTitle: Comparison of Aerobic and Resistance Training on Exercise Capacity, Depression and Quality of Life in Hypothyroidism. overallStatus: RECRUITING date: 2024-04-01 date: 2024-06-01 date: 2024-06-01 date: 2024-04-22 date: 2024-04-22 name: Riphah International University class: OTHER briefSummary: the study will show the effects of aerobic and resistance training on exercise capacity, depression and quality of life in patients with hypothyroidism. The evaluation of TSH level before and after the exercise sessions will provide valuable data. conditions: Comparison of Aerobic Exercise and Resistance Training studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 66 type: ESTIMATED name: aerobic exercises name: resistance training name: medication measure: 6 Minute Walk Test measure: The Beck Depression Inventory Scale measure: SF- 36 SF-36 sex: ALL minimumAge: 40 Years maximumAge: 60 Years stdAges: ADULT facility: Abbottabad medical complex status: RECRUITING city: Abbottābād state: Khyber Pakhtunkhwa zip: 21300 country: Pakistan name: saira jahan, MS role: CONTACT phone: 031591289095 email: saira.jahan@riphah.edu.pk name: Usama Iqbal role: PRINCIPAL_INVESTIGATOR lat: 34.1463 lon: 73.21168 hasResults: False